Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceHagop M. Kantarjian, Jörge E. Cortes, Mary Beth Rios et al.|Blood|2012Cited by 340
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J. Short, Elias Jabbour, Hagop Kantarjian et al.|Blood Advances|2022Cited by 120
Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNicholas J. Short, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2019Cited by 39